Reprogramming of a melanoma genome by nuclear transplantation.
Level 5 - mechanism / opinion, no new human data
Bench and animal research
PubMed 15289459 · doi:10.1101/gad.1213504
What was done
Researchers used nuclear transplantation into oocytes to test whether reprogramming could restore pluripotency to malignant cancer genomes. Donor nuclei from leukemia, lymphoma, breast cancer, and a RAS-inducible melanoma model were assessed for their ability to support preimplantation development to the blastocyst stage, yield embryonic stem cell lines, and produce multilineage chimeras in mice.
What was found
The abstract reports no numerical data. Nuclei from leukemia, lymphoma, and breast cancer supported development to the blastocyst stage but failed to produce embryonic stem cells. A blastocyst cloned from a RAS-inducible melanoma nucleus yielded embryonic stem cells capable of differentiating into melanocytes, lymphocytes, and fibroblasts in vivo. Chimeras derived from these cells developed cancer with higher penetrance, shorter latency, and an expanded tumor spectrum compared to the donor mouse model upon RAS reactivation.
Why it matters
This work demonstrates that the genome of a malignant melanoma cell retains developmental pluripotency when reprogrammed by an oocyte. It establishes a model system for evaluating the phenotypic effects of specific cancer genomes in the context of an intact animal.
Limits
The investigation was conducted exclusively in mouse models and cell lines, limiting direct clinical extrapolation. The abstract provides no sample sizes, blastocyst derivation rates, cloning efficiencies, or quantitative tumor survival metrics. Reprogramming to pluripotency failed for all tested non-melanoma cancer types.
Cited by
- contradicts Nuclear transfer experiments show that placing a cancer cell nucleus into a normal enucleated cytoplasm results in normal cell differentiation and suppresses tumor formation, contradicting the somatic mutation theory of cancer.